Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
ASSETS
Cash and cash equivalents	$ 28,744	$ 16,512
Marketable securities	82,767	18,061
Prepaid and other current assets	2,522	758
Total current assets	114,033	35,331
Property and equipment, net	41	57
Other assets	533	614
Total assets	114,607	36,002
Liabilities
Accounts payable	2,315	1,020
Accrued liabilities	2,123	2,486
Total current liabilities	4,438	3,506
Other long-term liabilities	155	254
Total liabilities	4,593	3,760
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2021 and December 31, 2020, respectively	0	0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,510,038 and 19,389,413 shares at March 31, 2021 and December 31, 2020, respectively; and outstanding, 59,498,958 and 19,378,333 shares at March 31, 2021 and December 31, 2020, respectively	60	19
Additional paid-in capital	544,601	458,748
Treasury stock, at cost; 11,080 shares at March 31, 2021 and December 31, 2020	(708)	(708)
Accumulated deficit	(433,613)	(425,550)
Accumulated other comprehensive loss	(72)	(13)
Total Caladrius Biosciences, Inc. stockholders' equity	110,268	32,496
Noncontrolling interests	(254)	(254)
Total stockholders' equity	110,014	32,242
Liabilities and Equity, Total	$ 114,607	$ 36,002